Clinical Trials: Crohn's Disease

Alabama

Birmingham; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Birmingham; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Mobile; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Montgomery; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Pell City; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Arizona

Tucson; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Arkansas

Fayetteville; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

California

Encinitas; Discovery Clinical Research
Clinical Trial Seeking Crohn's Disease Patients

La Jolla; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Orange; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Palo Alto; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Roseville; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

San Francisco; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Colorado

Colorado Springs; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Golden; Rocky Mountain Clinical Research, Inc.
A Pilot Study of the Safety and Efficacy of ALX-0600 in Subjects with Moderately Active Crohn’s Disease.

Golden; Rocky Mountain Clinical Research, Inc.
Active Crohn's Disease: International, Multicenter, Double-Blind, Placebo-controlled study for moderate to severe Crohn's Disease.

Golden; Rocky Mountain Clinical Research, Inc.
An investigational research trial to assess the safety and efficacy of a study drug in patients with active Crohn's disease.

Lakewood; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Lakewood; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Littleton; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Wheat Ridge; Western States Clinical Research, Inc.
New Research Takes Aim At Crohn's Disease

Wheat Ridge; Western States Clinical Research, Inc.
Crohn's Disease Clinical Research Study

Connecticut

Waterbury; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Florida

Boca Raton; Clinical Trials Management of Boca Raton, Inc
Study Investigating a novel oral treatment for Crohn's disease

Clearwater; Clinical Research of West Florida, Inc.
Crohn's disease research study

Clearwater; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Gainesville; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Hialeah; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Hollywood; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Jacksonville; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Jacksonville; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Jacksonville; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

New Port Richey; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

North Miami Beach; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

North Miami Beach; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Sarasota; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

St. Petersburg; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

St. Petersburg; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Winter Park; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Georgia

Marietta; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Savannah; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Illinois

Arlington Heights; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Chicago; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Chicago; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Chicago; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Lombard; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Indiana

Bloomington; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Kansas

Topeka; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Kentucky

Bowling Green; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Lexington; University of Kentucky Chandler Medical Center
Do you have Crohn’s disease or ulcerative colitis?

Lexington; University of Kentucky Chandler Medical Center
Do you have Crohn’s disease or ulcerative colitis?

Lexington; University of Kentucky Chandler Medical Center
Relatives of Inflammatory Bowel Disease Patients Needed for Health Questionnaire

Louisville; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Louisville; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Louisiana

Baton Rouge; Gulf Coast Research Associates, Inc.
Crohn's Disease

Baton Rouge; Gulf Coast Research Associates, Inc.
Crohn's Disease

Metairie; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Metairie; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Monroe; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Maryland

Annapolis; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Annapolis; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Chevy Chase; Metropolitan Gastroenterology Group/Chevy Chase Clinical Research
Safety and Efficacy of AST-120 in Mild to Moderate Crohn's Patients With Fistulas

Chevy Chase; Chevy Chase Clinical Research/Metropolitan Gastroenterology Group
Crohn's Disease - Working for a Better Tomorrow

Laurel; Maryland Digestive Disease Research, LLC
Crohn's Disease

Prince Frederick; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Townson; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Massachusetts

Newton; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Worcester; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Michigan

Chesterfield; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Chesterfield; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Dearborn; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Troy; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

West Bloomfield; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

West Bloomfield; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Minnesota

Rochester; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Rochester; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Mississippi

Ocean Springs; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Missouri

Kansas City; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Mexico; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

New Jersey

Cedar Knolls; Gastroenterology Research Associates, LLC
A Clinical Research Study for Adults with Moderately-to Severely-Active Crohn’s Disease

Egg Harbor Township; Atlantic Gastroenterology Associates
Do You Have Crohn's Disease? Have You Received Infliximab (Remicade) Therapy?

Egg Harbor Township; Atlantic Gastroenterology Associates
Do you suffer from Crohn's disease and have been unable to find a successful treatment option?

Egg Harbor Township; Atlantic Gastroenterology Associates
Do you have Crohn's Disease?

New York

Manhasset; Biomedical Research Alliance of New York
Crohn’s Disease - Adults

Mineola; Winthrop University Hospital Clinical Trials Center
This is a clinical research study for people with active moderate Crohn’s Disease.

Mineola; Winthrop University Hospital Clinical Trials Center
Volunteers needed for a pediatric Crohn’s Disease research study.

New Hyde Park; Biomedical Research Alliance of New York
Crohn’s Disease- Ages 6-17 years old

New York; Mount Sinai Medical Center
A Phase III, multicenter, placebo-controlled, randomized, double-blind study to evaluate the safety and efficacy of PROCHYMAL (ex vivo cultured adult human mesenchymal stem cells) intravenous infusion for the induction of remission in subjects experiencing treatment-refractory moderate-to-severe Crohns disease [603].

New York; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

New York; Mount Sinai Medical Center
Multi-site Trial of Azathioprine Dosing in Crohn?Æs Disease

New York; Mount Sinai Medical Center
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Human Anti-TNF Antibody Adalimumab for the Induction of Clinical Remission in Subjects With Crohn's Disease.
Protocol M02-403

New York; Mount Sinai Medical Center
A Phase IIIb multicentre, open label induction and double blind comparison of two maintenance schedules evaluating clinical benefit and tolerability of certolizumab pegol, a pegylated Fab fragment of humanized antibody to tumor necrosis factor(TNF) over 26 weeks in patients suffering from Crohn's disease with prior loss of response or intolerance to infliximab.[RPCE05F1501]

New York; Mount Sinai Medical Center
Double-blind, Randomized, Multicenter, Placebo controlled Phase II Study of Efficacy and Safety of HMPL 004 in Subjects with Active Moderate Crohn's Disease [200500401]

New York; Mount Sinai Medical Center
Multi-site Trial of Azathioprine Dosing in Crohn's Disease

Syracuse; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

North Carolina

Chapel Hill; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Charlotte; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Charlotte; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Charlotte; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Charlotte; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Charlotte; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Jacksonville; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Raleigh; Wake Research Associates
Crohn’s Disease?

Raleigh; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Raleigh; Wake Research Associates
Don’t let Crohn’s Disease keep you from your favorite activities

Raleigh; Wake Research Associates
Do you have suffer from Crohn's Disease?

Raleigh; Wake Research Associates
Research Study for Crohn's Disease

Raleigh; Wake Research Associates
Do you have Crohn's Disease?

Wilmington; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Ohio

Beachwood; Gastroenterology Associates of Cleveland, Inc.
Humira for Crohn's Disease

Beachwood; Gastroenterology Associates of Cleveland, Inc.
Research trial now enrolling for Humira ® for Crohn's Disease

Cincinnati; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Cincinnati; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Cincinnati; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Cleveland; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Cleveland; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Cleveland; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Dayton; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Dayton; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Oklahoma

Oklahoma City; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Tulsa; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Tulsa; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Pennsylvania

Beaver Falls; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Lancaster; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Tennessee

Germantown; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Germantown; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Germantown; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Texas

Houston; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

San Antonio; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Tyler; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Utah

Salt Lake City; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Virginia

Charlottesville; University of Virginia
Men and women 18-65 with active Crohn's disease wanted for study

Chesapeake; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Norfolk; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Richmond; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Washington

Seattle; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Seattle; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Seattle; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Spokane; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Tacoma; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Wisconsin

Milwaukee; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

International

Adelaide, Australia; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Box Hill, Australia; UCB Clinical Trial Call Center
Multi-Center, Open-Label Study to Evaluate Safety of Long Term Therapy of Certolizumab Pegol Patients With Crohn's Disease

Concord, NSW, Australia; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Footscray, VIC, Australia; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Fremantle, Australia; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Garran, Australia; UCB Clinical Trial Call Center
Multi-Center, Open-Label Study to Evaluate Safety of Long Term Therapy of Certolizumab Pegol Patients With Crohn's Disease

Garran, Australia; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Parkville, VIC, Australia; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Box Hill, Australlia; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Wien, AUSTRIA; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Bonheiden, Belgium; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Brussels, Belgium; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Gent, Belgium; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Leuven, Belgium; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Liege, Belgium; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Roeselare, Belgium; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Belo-Horizonte, BRAZIL; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Belo-Horizonte, MG, BRAZIL; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Goiania, BRAZIL; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Porto Alegre, Brazil; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Rio de Janeiro, BRAZIL; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Santo-Andre, BRAZIL; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Santos, BRAZIL; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Abbottsford, British Columbia, Canada; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Calgary, Canada; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Calgary, Canada; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Calgary, CANADA; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Calgary, Canada; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Edmonton, CANADA; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Edmonton, AB, Canada; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Hamilton, Canada; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Kelowna, BC, Canada; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Kingston, ON, Canada; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

London, CANADA; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

London, CANADA; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

London, ON, Canada; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

London, ON, Canada; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Saskatoon, Saskatchewan, Canada; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Toronto, CANADA; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Toronto, ON, Canada; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Toronto, ON, Canada; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Toronto, Ontario, Canada; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Vancouver, British Columbia, Canada; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Winnipeg, Canada; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Winnipeg, Manitoba, Canada; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Santiago, CHILE; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Vina del Mar, Chile; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Hradec Kralove, Czech Republic; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Hradek Kralove, Czech Republic; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Hradek Kralove, Czech Republic; UCB Clinical Trial Call Center
Multi-Center, Open-Label Study to Evaluate Safety of Long Term Therapy of Certolizumab Pegol Patients With Crohn's Disease

Liberec, Czech Republic; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Olomouc, Czech Republic; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Tabor, Czech Republic; UCB Clinical Trial Call Center
Multi-Center, Open-Label Study to Evaluate Safety of Long Term Therapy of Certolizumab Pegol Patients With Crohn's Disease

Usti nad Orlici, CZECH REPUBLIC; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Zlin, Czech Republic; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Tallin, Estonia; UCB Clinical Trial Call Center
Multi-Center, Open-Label Study to Evaluate Safety of Long Term Therapy of Certolizumab Pegol Patients With Crohn's Disease

Tallin, Estonia; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Tartu, Estonia; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Haemeenlinna, Finland; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Jyvaskylä, Finland; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Mikkeli, Finland; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Tampere, Finland; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Berlin, GERMANY; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Frankfurt, Germany; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Frankfurt, GERMANY; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Freiburg, GERMANY; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Heidelberg, Germany; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Homburg, GERMANY; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Jena, Germany; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Kiel, GERMANY; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Munchen, GERMANY; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Rodstak, Germany; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Ulm, Germany; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Ulm, GERMANY; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Ulm, Germany; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Wilhelmshaven, GERMANY; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Athens, Greece; UCB Clinical Trial Call Center
Certolizumab Pegol for Treatment of Adult Greek Population With Moderate to Severe Crohn's Disease, Who Failed on Infliximab

Athens, Greece; UCB Clinical Trial Call Center
Certolizumab Pegol for Treatment of Adult Greek Population With Moderate to Severe Crohn's Disease, Who Failed on Infliximab

Athens, Greece; UCB Clinical Trial Call Center
Certolizumab Pegol for Treatment of Adult Greek Population With Moderate to Severe Crohn's Disease, Who Failed on Infliximab

Athens, Greece; UCB Clinical Trial Call Center
Certolizumab Pegol for Treatment of Adult Greek Population With Moderate to Severe Crohn's Disease, Who Failed on Infliximab

Heraclion, Crete, Greece; UCB Clinical Trial Call Center
Certolizumab Pegol for Treatment of Adult Greek Population With Moderate to Severe Crohn's Disease, Who Failed on Infliximab

Ioannina, Greece; UCB Clinical Trial Call Center
Certolizumab Pegol for Treatment of Adult Greek Population With Moderate to Severe Crohn's Disease, Who Failed on Infliximab

Piraeus, Greece; UCB Clinical Trial Call Center
Certolizumab Pegol for Treatment of Adult Greek Population With Moderate to Severe Crohn's Disease, Who Failed on Infliximab

Thessaloniki, Greece; UCB Clinical Trial Call Center
Certolizumab Pegol for Treatment of Adult Greek Population With Moderate to Severe Crohn's Disease, Who Failed on Infliximab

Thessaloniki, Greece; UCB Clinical Trial Call Center
Certolizumab Pegol for Treatment of Adult Greek Population With Moderate to Severe Crohn's Disease, Who Failed on Infliximab

Thessaloniki, Greece; UCB Clinical Trial Call Center
Certolizumab Pegol for Treatment of Adult Greek Population With Moderate to Severe Crohn's Disease, Who Failed on Infliximab

Budapest, Hungary; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Budapest, Hungary; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Budapest, Hungary; UCB Clinical Trial Call Center
Multi-Center, Open-Label Study to Evaluate Safety of Long Term Therapy of Certolizumab Pegol Patients With Crohn's Disease

Budapest, Hungary; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Budapest, Hungary; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Gyor, Hungary; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Nagykanizsa, Hungary; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Szeged, Hungary; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Szombathely, Hungary; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Beer Sheva, Israel; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Beer Sheva, Israel; UCB Clinical Trial Call Center
Multi-Center, Open-Label Study to Evaluate Safety of Long Term Therapy of Certolizumab Pegol Patients With Crohn's Disease

Haifa, Israel; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Kfar Saba, Israel; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Petha Tikva, Israel; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Rehovot, Israel; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Tel Aviv, Israel; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Bologna, ITALY; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Bologna, ITALY; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Padova, ITALY; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Roma, Italy; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Roma, Italy; UCB Clinical Trial Call Center
Multi-Center, Open-Label Study to Evaluate Safety of Long Term Therapy of Certolizumab Pegol Patients With Crohn's Disease

Roma, Italy; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Torino, ITALY; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Riga, Latvia; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Riga, Latvia; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Riga, Latvia; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Riga, Latvia; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Valmiera, Latvia; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Auckland, New Zealand; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Auckland, New Zealand; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Christchurch, New Zealand; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Hamilton, New Zealand; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Newton, Wellington, New Zealand; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Czestochowa, POLAND; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Czestochowa, Poland; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Lodz, Poland; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Warszawa, Poland; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Warszawa, Poland; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Wroclaw, Poland; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Bucharest, Romania; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Bucharest, Romania; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Cluj Napoca, Romania; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Constanta, Romania; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Moscow, RUSSIAN FEDERATION; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Moscow, RUSSIAN FEDERATION; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

St. Petersburg, RUSSIAN FEDERATION; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Dniepropetrovsk, Ukraine; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Dniepropetrovsk, Ukraine; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Donetsk, Ukraine; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Kiev, Ukraine; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Kiev, Ukraine; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Kyiv, Ukraine; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Kyiv, Ukraine; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Lviv, Ukraine; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Simferopol, Ukraine; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease